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Studies suggest improved survival following resection of colorectal cancer liver metastases (CLMs). We investigated predictors of
survival among patients with CLM who underwent hepatic resection using the SEER-Medicare database to identify patients X65
years diagnosed with CLM, 1991–2003, who underwent hepatectomy. Cox proportional hazards models were used to identify
factors associated with survival after hepatectomy. Of 923 patients with CLM who underwent hepatectomy, 514 were stages I–III
and developed CLM46 months after diagnosis (metachronous), and 409 were stage IV with CLM at diagnosis (synchronous). From
the date of hepatectomy, 5 year survival was 22%; younger age, being married, female gender, surgery in an NCI-designated cancer
centre, fewer comorbidities, fewer positive lymph nodes, and lower grade were associated with improved survival. Both 5-fluorouracil
(5FU)-based chemotherapy and hepatic arterial infusion (HAI) of floxuridine-based chemotherapy following hepatectomy improved
survival (HR¼0.62, 95% CI: 0.50–0.78; HR¼0.51, 95% CI: 0.28–0.97, respectively) in the synchronous, but not metachronous,
group. The HR for overall mortality was higher in hospitals with a high vs low procedure volume (0.75, 95% CI: 0.58–0.94).
A substantial subgroup of patients with CLM who undergo hepatectomy experiences long-term survival. High hospital procedure
volume and use of 5FU-based or HAI-based chemotherapy after resection were associated with improved prognosis.
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Colorectal cancer is one of the most common cancers worldwide and
remains the second most common cause of cancer death in the
United States (Parkin et al, 2005). The liver is the most common
distant site of metastasis from colorectal cancer (70%) and is often
the only organ affected (Scheele et al, 1990; Stangl et al, 1994). Recent
reports indicate that liver metastases occur in more than 50000
patients with primary colorectal cancer each year in the United States
(Foster, 1978; Stangl et al, 1994; Blumgart and Fong, 1995).
Patients with liver metastases from colorectal cancer (CLM)
have a poor prognosis. Following diagnosis, the median survival of
untreated patients with CLM is 6–12 months. The median survival
is more than 24 months in patients treated with chemotherapy, but
they remain unlikely to be cured (Cady et al, 1970; Wilson and
Adson, 1976). Surgical resection of liver metastases is currently
considered first-line treatment, with alternative therapies, such as
radiofrequency ablation, reserved for those lesions that are not
amenable to resection (Gillams and Lees, 2005). In recent years,
however, advances in early diagnosis and surgical procedures
appear to offer better long-term survival and cure in patients with
limited CLM who are resectable, with a reported median survival
of 35–69 months. Large series report 5-year and 10-year survival
rates as high as 51 and 27%, respectively, following hepatectomy
in this setting (Scheele et al, 1995; Fong et al, 1999; Bolton
and Fuhrman, 2000; Sugawara et al, 2001; Choti et al, 2002; de
Santibanes et al, 2002; Adam et al, 2003).
The factors, which predict prognosis and survival after hepatic
resection for CLMs, have not been well defined. Furthermore, while
systemic chemotherapy is frequently administered after resection,
the optimal regimen and its contributions to survival outcomes are
inconclusive (Kemeny et al, 2002; Portier et al, 2006; Yoshida et al,
2006). We, therefore, conducted a population-based study to
investigate the impact of demographic, clinical, and treatment
characteristics on survival after hepatic resection for CLMs.
PATIENTS AND METHODS
Data sources
The primary data source for this study is a database created
through cooperative efforts by the National Cancer Institute’s
Surveillance, Epidemiology, and End Results (SEER) cancer
registry; the Center for Medicare & Medicaid Services (CMS);
and the National Cancer Institute. Developed in 1993 (Potosky
et al, 1993), the SEER-Medicare database links information on
patient demographics, tumour incidence, histology, location, stage,
treatment, and survival from the SEER programme, a cancer
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sregistry comprising a representative sample (approximately 25% at
the time of this study) of the US population, to the individual
medical insurance claims for cancer-related services (office visits,
diagnostic testing, and treatments) provided to patients 65 years of
age and older collected in the CMS Medicare database. The SEER-
Medicare database has been described in detail (Klabunde et al,
2000) and has been validated previously for documenting the use
of surgery (Cooper et al, 2002) and chemotherapy (Warren et al,
2002). This study was approved by the Columbia University
Institutional Review Board.
Patient selection criteria
We identified all persons within the SEER-Medicare database who
had a diagnosis of colorectal cancer from 1 January 1 1991 to 31
December 31 2003, 65 years of age or older, who at diagnosis or
later developed a diagnosis of liver metastasis (International
Classification of Diseases (ICD) 9th code: 197.7), and who
underwent a hepatic resection. Patients who were enrolled in a
health maintenance organisation at any point of time from 12
months before to 8 months after the diagnosis of CLM were
excluded due to the incompleteness of this information in the
database. We also excluded individuals with any gaps in Medicare
Parts A and B coverage during the study period. Subjects whose
metastases were coded within 180 days of their primary diagnosis
with American Joint Committee on Cancer (AJCC) stages I–III
were excluded from the study, since the primary diagnosis may
have been mis-staged (N¼85). Patients were further classified as
synchronous (n¼409) if a patient was diagnosed with AJCC stage
IV or colorectal cancer with liver metastasis, and metachronous
(n¼514) if the patient was diagnosed with stages I–III colorectal
cancer and subsequently developed liver metastases after 180 days.
Measurement of study variables
Patient characteristics Subjects were categorised by age group at
diagnosis, year of diagnosis, race/ethnicity, gender, marital status,
number of positive lymph nodes of primary colorectal cancer,
tumour grade (well/moderately differentiated or poorly differen-
tiated) of primary cancer, comorbidity score, residence (metro-
politan or non-metropolitan area), the type of hospital in which they
received care (teaching or non-teaching, NCI-designated cancer
centre) and the socioeconomic status (SES) of their census tract/zip
c o d e .W eo b t a i n e dd a t ao na g e ,r a c e ,g e n d e r ,m a r i t a ls t a t u s ,s u r g e r y ,
stage, tumour grade, lymph nodes, type of hospital, and area of
residence from the SEER database, NCI Hospital file, and AMA files,
and data on comorbid conditions and treatment from Medicare.
We generated an aggregate SES score from a hierarchy of
income data from the 2000 census. Patients were ranked on a 1–5
scale, with 1 as the lowest value, based on a formula incorporating
as many of the following as were available: median income in the
census tract of residence, median income in the zip code of
residence, census tract per capita income, zip code per capita
income; patients for whom all of these values were missing were
assigned to the lowest SES category.
To assess the prevalence of comorbid disease in our cohort, we
used the Klabunde adaptation of the Charlson comorbidity index
(Charlson et al, 1986; Deyo et al, 1992; Klabunde et al, 2000).
Medicare in-patient and outpatient claims were searched for
ICD-9-CM diagnostic codes, indicating a history of myocardial
infarction, congestive heart failure, peripheral vascular disease,
cerebrovascular disease, dementia; chronic pulmonary disease,
connective tissue disease, mild-to-severe liver disease, diabetes
with/without end-organ damage, haemiplegia, moderate-to-severe
renal disease, or AIDS, in the Medicare files from 12 months before
to 1 month after their diagnosis of cancer. Each condition was
weighted, and patients were assigned a score based on the
Klabunde–Charlson index (Klabunde et al, 2000, 2002).
Treatment characteristics Information on hepatectomy was
obtained by using an algorithm that searches and combines the
ICD-9-CM codes (50.21, 50.22, and 50.29 (wedge resection), 50.3
(lobectomy of liver), and 50.4 (total hepatectomy)) and Current
Procedural Terminology (CPT) codes (47120 (resection of liver
and partial lobectomy), 47122 (trisegmentectomy), 47125 (total
left lobectomy), and 47130 (total right lobectomy)). The hospital
procedure volume was defined based on the number of operations
performed by the given hospital in Medicare databases during the
study period as previously validated (Begg et al, 1998). The
hospitals were ranked by procedure volume: low (1–8), inter-
mediate (9–29), and high (30–125).
We defined other treatment exposures according to previously
published criteria for the SEER-Medicare database. Chemotherapy
exposure was derived through Medicare records and ICD-9 codes
(diagnosis and procedural), CPT and Healthcare Common
Procedure Coding System, and revenue centre codes. The status
of chemotherapy was classified as follows: hepatic arterial infusion
(HAI) of floxuridine (FUdR) (J9200 and C9426) with 5-fluorouracil
(5FU)-based (J9190) systemic chemotherapy, 5FU-based (J9190)
systemic chemotherapy alone, or no chemotherapy.
Survival
Survival time was analysed as the number of months from the
hepatectomy date to the Medicare date of death. Those alive at the
end of the follow-up period were classified as censored and
contributed the time interval from their diagnosis date to the end
of follow-up to the survival analysis. Overall survival is tracked on
a yearly basis for each subject in the SEER database.
Statistical analysis
Statistical analyses were conducted using SAS version 9.1. We
developed Cox proportional hazards regression models with all-
cause mortality as the dependent variable and type of chemotherapy,
age at diagnosis, race, SES, marital status, year of diagnosis, stage of
disease, tumour grade, type of hospital, and comorbidity score as the
independent variables for all subjects who had hepatectomy. Type of
liver resection was not included in the model, as it is not an
independent predictor of disease recurrence or overall survival after
surgical resection of metastases (Hamady et al, 2006; Zorzi et al,
2006). The Kaplan–Meier analysis was used to plot survival curves.
RESULTS
Baseline descriptive statistics
We identified 514 metachronous CLM patients and 409 synchro-
nous CLM patients, aged 65 years or older, diagnosed between
1991 and 2003 (Table 1). Most of the patients in the sample were
non-Hispanic whites (87%), and most resided in metropolitan
areas (91%). The overwhelming majority of patients (91%)
received care in teaching hospitals.
Some differences were noted in demographic, clinical, and
treatment characteristics between the two groups. More metachronous
than synchronous patients received their care in teaching hospitals
(93 vs 89%, P¼0.03) or NCI-designated cancer centres (36 vs 31%,
Po0.001). Similarly, more metachronous patients received their
resections in hospitals with high procedure volumes than
synchronous patients (47 vs 31%, respectively; P¼0.002).
After hepatectomy, fewer metachronous patients received
adjuvant chemotherapy than synchronous patients (36 vs 62%,
Po0.001). The use of hepatic infusion therapy was similar in both
groups. The median follow-up after resection for metachronous
patients was 26 months (range: 1–143 months), and 339 died
during the follow-up period. For synchronous patients, the median
follow-up was 25 months, and 296 died during the follow-up.
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sTable 1 Demographic, clinical, and treatment characteristics of synchronous and metachronous patients with colorectal cancer liver metastases who
underwent surgical resection, SEER-Medicare, 1991–2003
Characteristic Metachronous CLM Synchronous CLM All CLM
Total 514 409 923
Demographic characteristics
Age (years)
65–69 178 (35%) 122 (30%) 300 (32%)
70–74 193 (38%) 134 (33%) 327 (35%)
75–79 106 (21%) 81 (20%) 187 (20%)
80+ 37 (7%) 72 (18%) 109 (12%)
Race
White 441 (86%) 361 (88%) 802 (87%)
Black 25 (5%) 26 (6%) 51 (6%)
Other 48 (9%) 22 (5%) 70 (8%)
Sex
Female 291 (56%) 209 (51%) 500 (54%)
Male 223 (44%) 200 (49%) 423 (46%)
Socioeconomic status
1st quintile 99 (19%) 71 (17%) 170 (18%)
2nd quintile 96 (18%) 74 (18%) 170 (18%)
3rd quintile 108 (21%) 83 (20%) 191 (21%)
4th quintile 107 (21%) 96 (23%) 203 (22%)
5th quintile 104 (19%) 85 (21%) 189 (21%)
Marital status
Unmarried 136 (26%) 139 (34%) 275 (30%)
Married 362 (70%) 262 (64%) 624 (68%)
Unknown 16 (3%) 8 (2%) 24 (3%)
Area of residence
Metropolitan 467 (91%) 376 (92%) 843 (91%)
Rural 47 (9%) 33 (8%) 80 (9%)
Year of diagnosis of CLM
1991–1993 40 (8%) 64 (16%) 104 (11%)
1994–1996 96 (19%) 84 (21%) 180 (20%)
1997–1999 111 (21%) 89 (22%) 200 (22%)
2000–2003 267 (51%) 172 (42%) 439 (47%)
Clinical characteristics
Site of primary tumour
Rectal 146 (28%) 103 (25%) 249 (27%)
Colon 368 (72%) 306 (75%) 674 (73%)
Stage of primary colorectal cancer
I 71 (14%) 71 (7%)
II 162 (32%) 162 (18%)
III 281 (55%) 281 30%)
IV 409 (100%) 409 (44%)
Number of positive lymph nodes
0 210 (41%) 117 (27%) 327 (35%)
1–3 175 (34%) 153 (37%) 328 (36%)
X4 95 (19%) 96 (23%) 191 (21%)
Unknown 34 (7%) 43 (11%) 77 (8%)
Tumour grade of primary colorectal cancer
Well/moderately differentiated 406 (79%) 311 (76%) 717 (78%)
Poorly/undifferentiated 90 (18%) 85 (21%) 175 (19%)
Unknown 18 (3%) 13 (3%) 31 (3%)
Comorbidity score
0 315 (61%) 272 (67%) 587 (64%)
1 143 (28%) 97 (24%) 240 (26%)
41 56 (11%) 40 (9%) 96 (10%)
Treatment characteristics
Care in a teaching hospital
No 34 (7%) 37 (9%) 71 (8%)
Yes 476 (93%) 365 (89%) 841 (91%)
Unknown o5 (1%) o10 (2%) 11 (1%)
Care in NCI-designated cancer centre
No 329 (64%) 283 (76%) 612 (66%)
Yes 185 (36%) 126 (31%) 311 (34%)
Hospital procedure volume
Low (1–8) 125 (24%) 164 (40%) 289 (31%)
Medium (9–29) 147 (29%) 120 (29%) 267 (30%)
High (429) 242 (47%) 125 (31%) 367 (40%)
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In a multivariate Cox proportional hazards model, younger age,
fewer positive lymph nodes, and the receipt of care at hospitals with
higher procedure volume were associated with a reduction in overall
mortality in the overall sample (Table 2). Female gender, receipt of
care at an NCI-designated cancer centre, and receipt of adjuvant
chemotherapy for the primary tumour were associated with
improved survival in metachronous CLM patients. Among syn-
chronous CLM patients, single marital status, higher comorbidity
score, greater number of positive lymph nodes in the primary
colorectal cancer specimen, and poorly differentiated tumours were
all associated with increased mortality. Systemic 5FU-based
chemotherapy decreased mortality (HR 0.62, 95% CI: 0.50–0.78)
in the synchronous metastasis group. Similarly, HAI with FUdR
improved survival in the synchronous CLM group (HR 0.51, 95%
CI: 0.28–0.90), but not among the metachronous patients.
In an unadjusted Kaplan–Meier analysis, the 5-year overall
survival from hepatectomy was 25% among metachronous CLM
patients and 19% among synchronous CLM patients (P¼0.3119
for log-rank test) (Figure 1).
DISCUSSION
In this population-based study, we found that hepatic resection for
colorectal liver metastases resulted in an overall 5-year survival of
22% in elderly patients. Those who presented with liver metastases
at the time of diagnosis had similar survival to those subjects who
had a recurrence in the liver after an initial diagnosis of stages
I–III colorectal cancer. In addition, after adjustment for known
confounders of mortality, 5FU-based systemic chemotherapy
alone, HAI with FUdR with systemic chemotherapy, and higher
hospital procedure volume were each associated with improved
overall survival.
A recent population-based study investigated the benefits of
hepatic resection in colon cancer patients diagnosed with liver
metastases (Cummings et al, 2007). In this study, the investigators
evaluated the outcomes of patients who underwent resection to
those who did not. They found that stage IV colon cancer patients
who underwent hepatic resection of CLMs had improved survival
compared to those who did not (HR 2.78, 95% CI: 2.53–3.04). The
conclusions to be drawn from this study were limited due to the
inability to account for various factors that influence the decision
to perform hepatic resection, such as the presence of metastases
at other sites, the number of liver metastases, and the sizes of
the liver metastases. They also found that patients who presented
initially with stages I–III disease (metachronous) had better
survival than those who had hepatic metastases at the time of
diagnosis (synchronous), in contrast to our findings. However,
they measured survival from the time of the original cancer
diagnosis, and not from the time of hepatic resection. Thus, the
lead time of the progression from stages I–III till the occurrence of
the liver metastases and surgery would bias the results and
increase the observed survival of the metachronous group.
Presently, there is no standard guideline for CLM patients after
liver resection. There are a few randomised clinical trials published
that evaluate the survival effects of HAI of FUdR and/or intra-
venous systemic chemotherapy after hepatic resection (Lygidakis
et al, 1995; Asahara et al, 1998; Lorenz et al, 1998; Lorenz and
Muller, 2000; Tono et al, 2000; Kemeny et al, 2002; Kemeny and
Gonen, 2005; Portier et al, 2006). Most of these studies, however,
have limited statistical power due to small sample sizes (less than
100 subjects) or slow accrual. Among five studies in which HAI
with FUdR chemotherapy was compared with resection alone,
disease-free survival was reported to be better in patients with
adjuvant HAI of FUdR after resection in three studies (Lygidakis
et al, 1995; Asahara et al, 1998; Kemeny et al, 2002). An overall
survival benefit was observed in two of these studies (Lygidakis
et al, 1995; Asahara et al, 1998). The trial by Portier et al (2006)
evaluated the survival benefits of systemic intravenous adjuvant
chemotherapy and resection alone. Intravenous systemic che-
motherapy following hepatectomy improved disease-free survival
significantly (HR 0.66, 95% CI: 0.46–0.96). A trend to improved
overall survival was also observed, but was not statistically
significant (HR 0.73, 95% CI: 0.48–1.10). A very recent study
presented in abstract form from the EORTC randomised 364
patients to either surgery alone or perioperative FOLFOX (six
cycles preoperatively and six cycles postoperatively) (Nordlinger
et al, 2007). There was an improvement in progression-free
survival at 3 years for the chemotherapy arm, but not in overall
survival. Our observation that both HAI with FUdR and systemic
chemotherapy improved overall survival in the synchronous
metastasis group was consistent with these trials. The large sample
size in our study could be the reason that we observed statistically
significant survival benefits.
Interestingly, in our analysis, neither 5FU-based chemotherapy
nor HAI with FUdR use resulted in a survival benefit in patients
with metachronous CLM. No prior study has evaluated the
differential benefits of chemotherapy in synchronous vs meta-
chronous metastases separately. Our data suggest that 65% of
metachronous CLM patients had adjuvant systemic chemotherapy
administered following the initial resection of their primary
tumours. One possible explanation for the lack of a survival
benefit for post-hepatectomy chemotherapy could be due to
chemoresistance. Drug resistance has been reported to cause
treatment failure in 90% of metastatic cancer patients (Longley and
Johnston, 2005). Although not directly studied, their prior
exposure to 5FU-based chemotherapy may influence the efficacy
of chemotherapy at the time of liver recurrence. In contrast, the
synchronous patients are chemonaive and being treated for the
first time and so they may be more sensitive to chemotherapy.
A recent investigation found that in-hospital mortality after
hepatic resection was higher at lower volume hospitals. However,
Long-term mortality was not evaluated in the study (Dimick et al,
2003). We observed higher rates of long-term mortality at hospitals
with low procedure volume in our cohort (Table 2). Volume–
outcome studies are extensively used to assess variation in clinical
outcomes of surgical procedures (Begg et al, 1998; Schrag et al,
2000; Birkmeyer et al, 2002). Hospital procedure volume has been
Table 1 (Continued)
Characteristic Metachronous CLM Synchronous CLM All CLM
Adjuvant chemotherapy for primary cancer
Yes 182 (35%) NA NA
No 332 (65%)
Adjuvant chemotherapy after resection
Combined FUdR and 5FU therapy 40 (8%) 34 (8%) 74 (8%)
5FU-based therapy only 187 (36%) 256 (62%) 443 (48%)
No chemotherapy 287 (56%) 122 (30%) 409 (44%)
CLM¼colorectal cancer liver metastasis; 5FU¼5-fluorouracil; FUdR¼floxuridine; NA¼not applicable.
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sTable 2 Cox proportional hazards rate ratios for overall mortality associated with demographic, clinical, and treatment characteristics
Metachronous CLM (N¼514) Synchronous CLM (N¼409) All CLMs (N¼923)
Characteristics HR (95% CI)
a P-value HR (95% CI)




65–69 1.00 1.00 1.00
70–74 1.07 (0.85–1.35) 0.65 1.14 (0.95–1.46) 0.53 1.13 (1.00–1.28) 0.05
75–79 1.38 (1.06–1.81) 0.03 1.23 (0.99–1.53) 0.13 1.36 (1.09–1.69) 0.04
80+ 1.92 (1.38–2.66) o0.01 1.60 (1.18–2.18) 0.01 1.87 (1.46–2.34) 0.01
Race
White 1.00 1.00 1.00
Black 1.02 (0.63–1.66) 0.44 1.07 (0.81–1.23) 0.12 1.08 (0.85–1.38) 0.24
Other 1.09 (0.83–1.46) 0.12 0.97 (0.70–1.35) 0.63 0.91 (0.74–1.12) 0.44
Sex
Male 1.00 1.00 1.00
Female 0.81 (0.66–1.00) 0.04 1.04 (0.88–1.24) 0.70 0.92 (0.81–1.04) 0.62
Socioeconomic status
1st quintile 1.00 1.00 1.00
2nd quintile 0.94 (0.67–1.31) 0.13 0.96 (0.70–1.25) 0.43 1.04 (0.86–1.26) 0.35
3rd quintile 0.92 (0.68–1.63) 0.08 0.87 (0.66–1.13) 0.37 1.14 (0.93–1.39) 0.27
4th quintile 0.83 (0.67–1.13) 0.69 0.94 (0.72–1.23) 0.11 0.92 (0.75–1.12) 0.15
5th quintile 0.87 (0.64–1.11) 0.73 0.79 (0.61–1.03) 0.34 0.96 (0.78–1.17) 0.22
Marital status
Unmarried 1.00 1.00 1.00
Married 0.92 (0.73–1.17) 0.86 0.81 (0.67–0.96) 0.03 0.88 (0.77–1.01) 0.05
Area of residence
Metropolitan 1.00 1.00 1.00
Rural 1.25 (0.84–1.89) 0.58 0.98 (0.71–1.32) 0.51 1.11 (0.88–1.38) 0.21
Year of receipt of liver resection
1991–1993 1.00 1.00 1.00
1994–1996 1.01 (0.59–1.50) 0.94 0.87 (0.65–1.38) 0.17 0.91 (0.76–1.08) 0.07
1997–1999 0.96 (0.69–1.80) 0.66 0.81 (0.70–1.10) 0.22 0.85 (0.71–1.03) 0.08
2000–2003 0.78 (0.60–1.12) 0.58 0.78 (0.65–1.07) 0.46 0.82 (0.67–1.05) 0.11
Clinical characteristics
Site of primary tumour
Rectal 1.00 1.00 1.00
Colon 0.98 (0.61–1.57) 0.23 1.10 (0.83–1.46) 0.07 1.18 (0.98–1.28) 0.06
Tumour grade of primary cancer
Well/moderately differentiated 1.00 1.00 1.00
Poorly/undifferentiated 1.05 (0.78–1.41) 0.54 1.38 (1.14–1.66) o0.01 1.22 (1.06–1.41) 0.04
Unknown 0.97 (0.53–1.76) 0.71 1.34 (0.56–2.31) 0.43 1.32 (1.03–1.70) 0.03
Comorbidity score
0 1.00 1.00 1.00
1 1.01 (0.81–1.48) 0.71 1.12 (0.87–1.43) 0.46 1.07 (0.90–1.28) 0.15
41 1.27 (0.98–1.64) 0.39 1.52 (1.01–2.09) o0.01 1.29 (1.01–1.67) 0.05
Number of positive lymph nodes
0 1.00 1.00 1.00
1–3 1.11 (0.83–1.48) 0.53 1.81 (1.36–2.40) o0.01 1.41 (1.18–1.68) 0.02
X4 1.24 (0.88–1.75) 0.27 2.21 (1.75–2.66) o0.01 1.81 (1.51–2.19) 0.04
Unknown 0.96 (0.92–1.01) 0.05 1.06 (1.03–1.09) 0.04 1.04 (1.02–1.06) o0.01
Treatment characteristics
Care in teaching hospital
No 1.00 1.00 1.00
Yes 0.97 (0.69–1.38) 0.76 0.89 (0.72–1.09) 0.12 0.93 (0.078–1.11) 0.38
Care in NCI-designated cancer centre
No 1.00 1.00 1.00
Yes 0.78 (0.60–1.00) 0.05 0.86 (0.67–1.07) 0.29 0.92 (0.79–1.06) 0.51
Hospital procedure volume
Low (1–8) 1.00 1.00 1.00
Medium (9–29) 0.83 (0.65–1.04) 0.26 0.71 (0.55–0.92) 0.04 0.77 (0.58–0.94) 0.03
High (429) 0.79 (0.57–0.99) 0.04 0.65 (0.50–0.88) 0.02 0.75 (0.62–0.91) 0.02
Chemotherapy for primary cancer
No 1.00 NA NA
Yes 0.79 (0.62–0.97) 0.03
Chemotherapy after liver resection
No chemotherapy 1.00 1.00 1.00
5FU-based therapy only 0.99 (0.78–1.27) 0.10 0.62 (0.50–0.78) o0.01 0.76 (0.62–0.92) 0.02
HAI with FUdR and systemic 5FU 0.81 (0.25–2.26) 0.92 0.51 (0.28–0.97) 0.04 0.81 (0.42–1.57) 0.52
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ssuggested to represent part of institutional proficiency (Hodgson
et al, 2001). The differences in outcomes could be explained in part
by the variation of skills of surgeons in these hospitals. However,
we observed no relation between individual surgeon case volume
and overall survival (data not shown). Survival differences among
hospitals with different procedure volumes may facilitate some
strategies to improve quality of care. Once the top-performing
centres are identified, closer examinations of detailed intraopera-
tive or postoperative care may highlight some important factors
that are relevant to prognosis and survival after hepatectomy.
We performed a population-based study using data from a large
cohort that covered CLM cases from the SEER regions around the
country. Most of the medical literature regarding hepatectomy for
CLM consists of small single-institution, retrospective series. While
powerful for examining cancer treatment on a population level,
SEER-Medicare analyses rely on the use of administrative data
collected by the Center for Medicare & Medicaid Services to interpret
provider practices and care for individual patients tracked in the
SEER tumor registry. It should also be appreciated that our study
spans a relatively lengthy period of time over which surgical
techniques and chemotherapy practices will have varied somewhat.
A number of important sociodemographic and other variables,
such as performance status and patient preference towards
treatment, are not measured by these data and thus cannot be
included in predictive models to better assess important issues
related to cancer outcomes, including medical decision making and
patient preferences for care. Performance status has been shown to
be associated with clinical outcomes, and while we controlled for
comorbidities and age, poor performance status may have been
associated with both access to care and poor outcome. We also do
not have information on the individual serum carcinoembryonic
antigen levels or the specific nature of the metastases in each
patient, for example, the number of metastases, sizes of metastases,
and other sites of metastases (Minagawa et al,2 0 0 6 ) .
Our study confirms that the survival benefits observed in small
single institutional studies of hepatic resection for CLM can be
observed now on a population scale. Furthermore, hepatic
resection for liver metastases can be used in elderly patients with
good survival outcomes. In terms of clinical practice, our results
suggest that elderly patients with resectable colorectal liver
metastases who undergo surgical resection may benefit from
adjuvant 5FU-based chemotherapy. It appears that both systemic
chemotherapy and HAI improve outcomes after resection. In an
elderly population, the outcomes of hepatic resection are impacted
by hospital procedure volume, and the use of 5FU-based systemic
chemotherapy and/or HAI with FUdR. The benefits of systemic
therapy were recently confirmed by a randomised trial (Nordlinger
et al, 2007). Future studies need to better delineate patient,
clinician, and hospital characteristics that will lead to improved
outcomes for colorectal cancer patients with surgically resectable
liver metastases.
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